NVCT on Nasdaq

Nuvectis Pharma, Inc.

We are a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerNVCT on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersFort Lee, New Jersey1
  • Incorporated inDE2
  • Business address1 Bridge Plaza, Suite 275, Fort Lee, Nj 070242
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We seek to develop drug candidates in the precision medicine space, and our processes for selection and clinical development of drug candidates are based on scientific data into cancer-promoting factors, as well as our understanding of the clinical landscape and regulatory requirements.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income4567-$27.6M in 2025+114% since 2021
-$30.0M-$20.0M-$10.0M02021: -$12.9M-$12.9M20212022: -$19.2M-$19.2M2022+49%2023: -$22.9M-$22.9M2023+19%2024: -$19.8M-$19.8M2024−13%2025: -$27.6M-$27.6M2025+39%
Net income4567-$26.4M in 2025+105% since 2021
-$30.0M-$20.0M-$10.0M02021: -$12.9M-$12.9M20212022: -$19.1M-$19.1M2022+48%2023: -$22.3M-$22.3M2023+17%2024: -$19.0M-$19.0M2024−15%2025: -$26.4M-$26.4M2025+39%

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
Research and development$18.2M$12.9M
General and administrative$9.4M$6.9M
OPERATING LOSS-$27.6M-$19.8M
Finance income$1.1M$847.0K
NET LOSS-$26.4M-$19.0M
EFFECT OF WARRANTS MODIFICATION, see Note 6-$2.4M
TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS-$28.9M-$19.0M
BASIC NET LOSS PER COMMON SHARE OUTSTANDING, see Note 8-$1.32-$1.11
DILUTED NET LOSS PER COMMON SHARE OUTSTANDING, see Note 8-$1.32-$1.11
Basic weighted average number of common shares outstanding21.8M shares17.1M shares
Diluted weighted average number of common shares outstanding21.8M shares17.1M shares

Compare Nuvectis Pharma, Inc. with another company

Leadership

Who has led Nuvectis Pharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ron Bentsur2022–now

Chair

  1. Ron Bentsur2022–now
2025
Board members and other officers (6)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJames Oliviero named Aug 10, 202217

Timeline

  1. Feb 8, 2022New chief executive Ron Bentsur becomes CEO10

Filings

268 filings to the SEC since October 2021: 6 annual reports, 14 quarterly reports, 37 major events, 139 insider forms, 14 large holders, 2 private raises, 56 other. The latest 20:

  1. Aug 28, 2026EFFECT EDGAR
  2. Aug 21, 2026S-3 EDGAR
  3. Aug 21, 20268-K EDGAR
  4. Aug 6, 2026SCHEDULE 13G EDGAR
  5. Aug 5, 20264 OWNERSHIP DOCUMENT EDGAR
  6. Aug 4, 202610-Q EDGAR
  7. Aug 4, 20268-K EDGAR
  8. Jul 1, 20264 OWNERSHIP DOCUMENT EDGAR
  9. Jul 1, 20264 OWNERSHIP DOCUMENT EDGAR
  10. Jun 30, 20268-K EDGAR
  11. Jun 30, 2026424B5 EDGAR
  12. Jun 29, 2026424B5 EDGAR
  13. Jun 29, 20268-K EDGAR
  14. Jun 23, 20268-K EDGAR
  15. Jun 12, 20264 OWNERSHIP DOCUMENT EDGAR
  16. Jun 12, 20264 OWNERSHIP DOCUMENT EDGAR
  17. Jun 12, 20264 OWNERSHIP DOCUMENT EDGAR
  18. Jun 12, 20264 OWNERSHIP DOCUMENT EDGAR
  19. Jun 12, 20268-K EDGAR
  20. May 5, 202610-Q EDGAR

The 268 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

134 open-market trades by officers, directors and large owners since October 2021: 133 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 30, 2026Mosseri Marlio Charles10% ownerBuy50,000$18.32$916.0KForm 4
Jun 30, 2026BENTSUR RONChairman & CEOBuy12,500$20.00$250.0KForm 4
Nov 5, 2025BENTSUR RONChairman & CEOBuy5,000$5.72$28.6KForm 4
Nov 5, 2025Sanchez JuanDirectorBuy13,000$5.79$75.3KForm 4
Nov 5, 2025Kaplan Matthew L.DirectorBuy11,000$5.84$64.2KForm 4
Oct 27, 2025Mosseri Marlio Charles10% ownerBuy72,836$6.28$457.4KForm 4
Oct 24, 2025Mosseri Marlio Charles10% ownerBuy35,034$6.15$215.5KForm 4
Oct 23, 2025Mosseri Marlio Charles10% ownerBuy46,900$6.06$284.2KForm 4
Jun 20, 2025Mosseri Marlio Charles10% ownerBuy5,603$7.99$44.8KForm 4
Jun 18, 2025Mosseri Marlio Charles10% ownerBuy28,043$8.05$225.7KForm 4
Jun 17, 2025Mosseri Marlio Charles10% ownerBuy5,399$8.11$43.8KForm 4
May 12, 2025Mosseri Marlio Charles10% ownerBuy21,167$8.11$171.7KForm 4
May 9, 2025Mosseri Marlio Charles10% ownerBuy25,062$8.94$224.0KForm 4
May 8, 2025Mosseri Marlio Charles10% ownerBuy2,600$8.96$23.3KForm 4
May 8, 2025Mosseri Marlio Charles10% ownerBuy2,650$8.65$22.9KForm 4
May 7, 2025Mosseri Marlio Charles10% ownerBuy12,317$8.59$105.8KForm 4
May 6, 2025Mosseri Marlio Charles10% ownerBuy12,444$8.59$107.0KForm 4
Feb 7, 2025Mosseri Marlio Charles10% ownerBuy240,000$5.00$1.2MForm 4
Dec 24, 2024BENTSUR RONChairman & CEOBuy4,500$4.65$20.9KForm 4
Dec 13, 2024Mosseri Marlio Charles10% ownerBuy17,000$4.70$79.9KForm 4

All 134 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 27, 2022Raised $15.9 million in a private offering of equity Form D: 19 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 83. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Tang Capital Management LLC1,550,000$28.5M1.3%New
BlackRock, Inc.1,001,285$18.4M0.0%+236,844
Perceptive Advisors LLC1,000,000$18.4M0.3%New
Soleus Capital Management, L.P.1,000,000$18.4M0.6%New
Vanguard Capital Management LLC872,482$16.0M0.0%+212,603
Iridian Asset Management Llc/ct777,078$14.3M4.9%+125,321
Geode Capital Management, LLC432,273$8.0M0.0%+48,168
Occam Crest Management LP357,147$7.4M4.1%−50,000
Sphera Funds Management Ltd.382,945$7.0M1.0%New
Baldwin Wealth Partners Llc/ma382,015$7.0M0.5%+3,390
Alyeska Investment Group, L.P.275,000$5.1M0.0%New
State Street Corp248,198$4.6M0.0%+81,682
Susquehanna International Group, Llp217,286$4.0M0.0%+112,000
Avidity Partners Management LP200,000$3.7M0.6%New
Kalehua Capital Management LLC200,000$3.7M1.2%New
Northern Trust Corp146,714$2.7M0.0%+22,502
Vanguard Fiduciary Trust Co127,554$2.3M0.0%+12,712
Vanguard Portfolio Management LLC118,297$2.2M0.0%+26,143
Citadel Advisors LLC115,532$2.1M0.0%+37,107
Oppenheimer & Co Inc73,566$1.4M0.0%No change
UBS Group AG69,200$1.3M0.0%+30,637
Forbes J M & Co Llp59,000$1.1M0.1%No change
Charles Schwab Investment Management Inc57,133$1.1M0.0%+7,488
Informed Momentum Co LLC47,168$867.4K0.1%New
Nuveen, LLC40,823$750.7K0.0%+24,074

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24